SYNTHESIS, CRYSTAL STUDIES AND PHARMACOLOGICAL ROLE PREDICTION OF 3-IODO-2- METHYL-1 PHENYL SULFONYL-1H INDOLE by CHINNATHAMBI, RAMATHILAGAM et al.
Vol 10, Issue 3, 2017
Online - 2455-3891 
Print - 0974-2441
SYNTHESIS, CRYSTAL STUDIES AND PHARMACOLOGICAL ROLE PREDICTION OF 3-IODO-2-
METHYL-1 PHENYL SULFONYL-1H INDOLE
RAMATHILAGAM CHINNATHAMBI1*, VIJAYASRI SANTHANAM2, MANIVANNAN VADIVELU3, 
UMARANI PADAGACHERI RAMACHANDRAN4, WAHEETA HOPPER2
1Department of Physics, D. G. Vaishnav College, Chennai, Tamil Nadu, India. 2Department of Biotechnology, Faculty of Engineering and 
Technology, SRM University, Kattankulathur, Chennai, Tamil Nadu, India. 3Department of Physics, Presidency College (Autonomous), 
Chennai, Tamil Nadu, India. 4Joint Director of Collegiate Education (Planning & Development) (Retd) Department of Higher Education, 
Chennai, India. Email: cramathilagam1@gmail.com
Received: 18 November 2016, Revised and Accepted: 01 December 2016
ABSTRACT
Objective: Indole-based compounds have established many pharmacological applications. Indole acts as a starting compound for various medicinal 
preparations. Our objective is to determine the possible pharmacological roles of our crystallized indole-based ligand using computational approach. 
The activities studied are antibacterial, antitubercular, and antimelanoma.
Methods: The structure of the indole compound, CR2 was studied using single crystal X-ray diffraction technique. To predict the pharmacological 
activities, the structure-based docking method was followed. The protein targets were selected based on their important biological role in each 
activity mentioned above. The interactions between the targets and the crystal ligand were studied using a generic based docking algorithm. The 
significant pharmacophore features of the ligand were also reported.
Results: The ligand showed bonded and non-bonded interactions with the crucial amino acid residues of the active site of each target. The interactions 
and the binding energies were quite comparable to the targets’ natural ligands.
Conclusion: We suggest through the computational approaches that the ligand may have antitubercular, antibacterial, and antimelanoma activities 
with respect to the targets considered. The new insights of this compound as predicted by the computational methods are believed to provide a 
platform for the futuristic pharmacological activities of this compound that can be further considered for wet lab techniques.
Keywords: Indole, Dihydrofolate reductase, DNA gyrase, Human B-Raf kinase, Docking, Pharmacophore, Single crystal X-ray diffraction.
INTRODUCTION
Indole derivatives have displayed versatile pharmacological activities 
such as antimicrobial, antiviral, antihepatitis B virus, antifungal, 
antihuman immunodeficiency virus, antitubercular, antihypertensive, 
analgesic anti-inflammatory, anticancer, antidiabetic, and anti-convulsant 
agents [1]. These effects have been well proved in randomized controlled 
studies. Indole structure finds use in research as a starting material for 
the synthesis of larger, usually bioactive structures [2]. The importance 
of indole nucleus is well established in the field of pharmaceutical 
chemistry, plants, and animal biochemistry, and thus it has applications 
across a wide range of therapeutic areas [3]. Due to its pharmacological 
relevance, it is not surprising that the indole ring system has become 
an important building block or intermediate in the synthesis of many 
pharmaceutical agents. Since indole-based structures are capable of 
binding to many receptors with high affinity, they have been referred as 
privileged structures. Hence, the synthesis of several substituted indoles 
and the study of their crystal, molecular structure, and molecular 
docking studies continue to be an interesting field of research [4]. 
Docking is frequently used to predict the binding orientation of small 
molecules to the protein targets to predict the affinity and activity of the 
small molecule [5-7]. With this background information, a new indole 
derivative was synthesized. The synthesized compound was subjected to 
single crystal X-ray studies to investigate their molecular structure. The 
chemical structure of this derivative, 3-Iodo-2-methyl-1-phenylsulfonyl-
1H indole (CR2) was mapped to possible anti-tubercular, antibacterial, 
and anti-melanoma activities using computational approaches. For 
this study, the three important biological targets such as dihydrofolate 
reductase (DHFR) of Mycobacterium tuberculosis, DNA gyrase B of 
Staphylococcus, and B-Raf kinase of human have been considered. The 
interactions of the ligand CR2 with the active site residues were studied 
using a generic algorithm based molecular docking, and the binding 
modes have been investigated. This was followed by the mapping of 
pharmacophore features of the ligand to understand the interactions in 
a better way. In addition, an in silico study of the ADME properties of the 
compound was conducted by investigating their Lipinski’s parameters, 
topological polar surface area (TPSA), and percentage of absorption (% 
ABS). Here, we report the synthesis, crystal studies and computational 
molecular docking studies of 3-Iodo-2-methyl-1-phenylsulfonyl-1H 
indole (CR2). The studies done through the computational methods will 
help in understanding the novel pharmacological roles of CR2. The study 




3-Iodo-2-methyl indole (5 g and 0.02 mmol) was dissolved in distilled 
benzene (100 ml). To this, benzenesulfonyl chloride (3.23 ml and 0.025 
mmol) and 60% aqueous NaOH solution (40 g in 67.0 ml) were added 
along with tetra butyl ammonium hydrogen sulfate (1.0 g). This two-
phase system was stirred at room temperature for 2 hrs. It was then 
diluted with water (200 ml) and the organic layer was separated. The 
aqueous layer was extracted with benzene (2×20 ml). The combined 
organic layer was dried (Na2SO4). The benzene was then removed 
completely, and the crude product was recrystallized from methanol.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i3.16231
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X-ray crystallographic analysis
A single crystal of the title complex suitable for X-ray structural 
analysis is selected from the crystals obtained above. All measurements 
were made on a Bruker Kappa APEX-II diffractometer with graphite 
monochromated Mo-Kα radiation of 0.71073 Ǻ. The structure was 
solved by direct methods and refined by full-matrix least squares on F2 
using SHELXS97 [8]. Molecular graphics are drawn by PLATON [9]. All 
non-hydrogen atoms were refined anisotropically. The H atoms were 
introduced in calculated positions and refined with fixed geometry 
with respect to their carrier atoms [10]. The crystallographic data and 
refinement parameters are listed in Table 1. Only the selected bond 
distances are given in Table 2.
Preparation of ligand structure
The ligand structure was constructed using Chem BioDraw ultra 11.0 
software (Molecular modeling and analysis; Cambridge Soft) shown 
in Fig. 1 and its Oak Ridge Thermal Ellipsoid Plot diagram is shown in 
Fig. 2.
Computational study
For the compound (CR2), the important physicochemical property 
which includes Lipinski’s parameters, TPSA, and % ABS were 
determined using molinspiration. To be pharmacologically favorable 
the compound should have pharmacokinetic and toxic properties. The 
rational drug designing approach relies on the prediction of molecular 
interactions between the target and the drug candidate. To propose 
the possible biological activities of CR2, the molecular docking was 
performed with the important targets of pharmacological importance 
using a generic algorithm based approach. The three main roles to 
be demonstrated using computational methods are antitubercular, 
antibacterial, and antimelanoma. The three-dimensional structures 
of the targets were downloaded from the PDB [11]. To elucidate the 
compound’s antitubercular activity, the crystal structure of DHFR of 
M. tuberculosis in complex with NADPH and methotrexate (PDB code: 
1DF7) was considered as target. The three-dimensional structure 
of DHFR of M. tuberculosis reveals opportunities for the design of 
novel tuberculosis drugs [12]. DHFR catalyzes the NADPH-dependent 
reduction of dihydrofolate to tetrahydrofolate, and this is essential for 
the synthesis of thymidylate, purines, and several amino acids. Inhibition 
of the enzyme’s activity leads to the arrest of DNA synthesis and cell 
death. Hence, the inhibitors of this enzyme may control the population 
of this mycobacterium. The crystal structure of Staphylococcus Gyrase 
in complex with novobiocin (PDB code: 4URO) was used in docking 
studies to describe the antibacterial role [13]. DNA gyrase of bacteria 
is an essential topoisomerase that supercoils DNA through a process 
of strand breakage/resealing and DNA wrapping [14]. DNA gyrase is 
also the target for quinolone-based antibacterial agents which act 
by subverting the enzyme into a DNA damaging agent. Novobiocin 
binds to DNA gyrase, and blocks adenosine triphosphatase activity. 
The anti-melanoma activity was predicted using the interaction data 
between CR2 and Human B-Raf Kinase (PDB code: 3C4C), which is co-
crystallized with an inhibitor named PLX4720 [15]. The binding modes 
of the compound with the protein targets were studied using a well-
known generic algorithm based iGemDock v2. 1. The pharmacological 
interactions between the compound and the targets were studied for 
the better understanding of ligand binding mechanisms. iGemDock is 
an interactive graphical generic evolutionary method for molecular 
docking for computing ligand conformations and orientations relative 
to the active site of target proteins [16]. The binding sites for the three 
targets were prepared by considering a radius of 8 Å with co-crystal 
ligands as the center. The co-crystal ligands were also included in 
the docking procedure to check the efficacy of the protocol followed. 
All ligands were prepared for the correctness of their structures 








Volume 1435.49 (6) Å3
Density 1.838 Mg m−3
Temp 295 K
Unit cell dimensions a=10.7068 (3) Å
b=16.2670 (4) Å
c=8.5147 (2) Å
Final R indices (I>2σ [I]) R1 0.043
Goodness-of-fit on F 1.06
Melting point 395−397 K
MW: Molecular weight
Table 2: Selected bond distances of CR2
Bond Distance (Å) Bond Distance (Å)
C1-C2 1.381 (4) C12-C13 1.387 (5)
C2-C3 1.386 (6) C13-C14 1.392 (4)
C3-C4 1.367 (7) C14-N1 1.411 (3)
C4-C5 1.375 (6) C1-C6 1.380 (4)
C5-C6 1.384 (5) C1-S1 1.759 (3)
C7-C8 1.355 (4) C8-I1 2.050 (3)
C8-C9 1.421 (4) C9-C14 1.399 (4)
C9-C10 1.399 (4) N1-S1 1.667 (2)
C10-C11 1.365 (5) O2-S1 1.416 (3)
C11-C12 1.379 (5) O1-S1 1.411 (3)
Fig. 1: Schematic diagram of CR2
Fig. 2: Oak Ridge Thermal Ellipsoid Plot diagram of CR2
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beforedocking. Standard docking procedure with default genetic 
algorithm setting of 200 population size, 70 generations, and two 
solutions were followed. Each ligand was associated with a fitness 
score, which is the summation of bonded and non-bonded interactions. 
The non-bonded interactions include van der Waals and electrostatic 
contacts. The interaction profiles were created for each docking run, 
and the fitness scores were evaluated. The interactions were viewed 
using LigPlot+ [17]. The molecular interactions can be better explained 
in terms of the features present in the ligand. This is technically called 
as pharmacophore and is defined as the spatial arrangement of the 
features that is essential for a molecule to interact with a specific target 
receptor. It is an important strategy followed in rational drug designing. 
The ligand-based pharmacophore model was created for CR2 and a 
comparison with the other ligands used in the docking study was also 
attempted to explain the interaction in a more contented manner. The 
pharmacophore study was done using multiple flexible alignments 
using PharmaGist [18].
RESULTS AND DISCUSSION
The oral ABS of the newly synthesized derivative was tentatively 
assessed using theoretical calculations following Lipinski’s rule of five, 
which establishes that the ABS or permeation of an orally administered 
compound is more likely to be good if the drug satisfies the following 
criteria: (a) Hydrogen bond donors ≤5 (OH and NH groups); 
(b) hydrogen bond acceptors ≤10 (N and O atoms); (c) molecular weight 
<500; (d) calculated logP <5; (e) solubility (LogS) > −4. Compounds 
violating more than one of these rules may present bioavailability 
problems. The percentage of ABS was estimated using the equation: 
% ABS=109−0.345×TPSA. The important physicochemical parameters 
are listed in Table 3. The prominent physicochemical properties of CR2 
favor the Lipinski’s rule of five, thus, proving its better oral ABS using 
molinspiration. It can also be noticed that the compound has satisfied 
the criteria specified in ADMET/Tox screening as tabulated in Table 4 
proving that it is pharmacokinetically acceptable.
The docking results indicate that the compound has favorable bonded 
and non-bonded interactions with three targets specified. The fitness 
scores of the ligand with the three targets were comparable with that of 
co-crystal ligands (Table 5).
With respect to docking with DHFR, the common interactions 
observed between compound and co-crystal ligand were with D27, 
Q28, F31, and nucleotide 5′-diphosphate (NDP). The contribution 
through van der Waals interaction superseded the bonded interaction. 
The co-crystal ligand methotrexate showed a better interaction which 
is evident from the fitness score. This proves that the docking protocol 
followed is appropriate for the given target. The ligand also exhibits 
a similar kind of interaction indicating its activity as an inhibitor of 
DHFR of M. tuberculosis. Methotrexate showed bonded and non-
bonded interactions with the co-factor NDP. This interaction with co-
factor could be a possible reason for its inhibition activity. Similarly, 
the compound CR2 also exhibited hydrogen bonding and van der 
Waals interaction with the co-factor. The carbon atoms present in 
the indole ring were found to have van der Waals interaction with 
the NDP. Similarly, iodine atom in the compound made an external 
linking with the NDP. Structurally, the ring carbon atoms of the 
ligands are exposed to the solvent surface. The ligand was found to 
have favorable hydrophobic interactions with I20, L24, Q28, R23, and 
F31. There was a hydrogen bond formation between I atom attached 
to the indole ring with N atom of A7. A hydrogen bond was also seen 
between N of the indole ring with the OD2 atom of D27, which is 
one of the most crucial active site residues with which the co-crystal 
ligand also shares interaction. Similarly, the O1 atom attached to S had 
a bonded interaction with NE1 atom of W22. All these, amino acids 
were found to be in a binding pocket that was also preferred by the 
co-crystal inhibitor methotrexate. Through LigPlot, it was found that 
the hydrophobic interactions between NDP, P51, Q28, F31, D27, and 
I94 with these three ligands were found to be equivalent. The side 
chain interactions of the ligands with D27and I94 were found to 
be equivalent. The sulfur present in the ligand maintained van der 
Waals interaction with the NDP and D27. Most of the non-bonded 
interactions were contributed by the ring carbon atoms. Docking 
results indicate that the compound has strong interactions with the 
NDP and crucial amino acids present in the active site (Fig. 3). These 
results suggest that the CR2 could function as antitubercular agent 
targeting this protein.
To study the antibacterial effect, CR2 was docked with the crystal 
structure of DNA Gyrase B of Staphylococcus. The interactions were 
compared with the co-crystal ligand novobiocin, an antibiotic derived 
from Streptomyces knives. Hydrogen bonding with R200 (D chain) 
and van der Waals interactions with P87 and R144 were found to be a 
common interaction pattern between CR2 and novobiocin. Non-bonded 
interactions through van der Waals forces dominate the binding 
Table 3: Physico-chemical properties of CR2
Compound code % ABS TPSAa (A2) nHBAa (NO) nHBDa (OHNH) logPa MWa n violations Log Sb
CR2 95.51 39.076 3 0 4.368 397.237 0 −3.03
Prediction servers: awww.molinspiration.com; bwww. organic-chemistry.org/prog/peo. ABS: Absorption, TPSA: Topological polar surface area, MW: Molecular weight
Table 4: ADME/Tox screening for CR2
Parameters MW Dr Ar FB RB #R RL C nC nC/C #Chrg Chrg LogP PSA
Parameter standards 200-400 0-6 0-12 0-15 0-50 0-7 0-12 5-2 >2 0.1-1.0 0-3 (-2)-2 (-2)-6 0-150
CR2 397.23 0 3 2 18 2 9 15 5 0.33 0 0 4.28 47.45
MW: Molecular weight; Dr: Hydrogen donors; Ar: Hydrogen acceptors; FB: Flexible bonds; RB: Rigid bonds; #R: Ring number; RL: Ring size; C: Atom number; Nc: Non 
carbons; NC/C: Ratio hetero/carbon; #Chrg: Charge number; Chrg: Total charge; PSA: Polar surface area
Table 5: Docking scores (fitness energy kcal/mol) of ligands with the targets
Target Compound Energy VDW HBond Elec
Dihydrofolate reductase of Mycobacterium tuberculosis 1DF7 CR2 −83.0247 −65.0459 −17.9788 0
Methotrexate −176.665 −123.335 −48.611 −4.71911
Gyrase of Staphylococcus 4URO CR2 −94.4852 −83.1669 −11.3183 0
Novobiocin −148.471 −116.699 −31.7716 0
Human B-Raf kinase 3C4C CR2 −90.8108 −81.2444 −9.56638 0
PLX4720 −111.463 −105.208 −6.25468 0
Energy: Total energy, VDW: van der Waals, HBond: Hydrogen bond, Elec: Electrostatic forces
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between the ligands and the target, which amount to about 90% in 
case of CR2. The contribution of hydrogen bond to the total binding 
score is higher in case of novobiocin which could possibly be due to 
the presence of more oxygen atoms in its structure. The carbon atoms 
present in the indole ring of the compound are exposed to the solvent 
surface. The oxygen atoms attached to the sulfur atom of the compound 
is found to have hydrogen bond with side chains of D89 and Q91. These 
interactions are confined to chain A. Another noted interaction was also 
seen in the docking result which is the hydrogen bond with R200 of 
chain D (Fig. 4). Although the pattern of binding with the target varies 
between the ligands, the amino acids remain the same. That is, both 
the ligands bind to the crucial active site residues. The iodine atom 
present in the compound was not involved in any kind of interaction. 
The docking studies indicate the preference of ligands toward the same 
binding pocket. These observations recommend the candidate ligand 
CR2 to be antibacterial agent inhibiting this target protein.
The ligand, CR2 was docked with human Braf-kinase along with its 
selective inhibitor PLX4720. The docking results showed that the 
compound and co-crystal preferred the same binding site, which was 
spanned by L514, I527, K483, V471, T529, V471, and F583 (Fig. 5). Only 
the type of bonding differed between the ligands considered; the amino 
acids remain the same. The atom O2 of the ligand formed hydrogen 
bonds with NZ of K483 and N of D594. The docking results showed that 
the van der Waals interaction favored the binding of compound with 
protein. The iodine atom present in the compound was not involved 
in any kind of interaction. Both the ligands such as CR2 and selective 
inhibitor PLX4720 share some structural features in common such as 
indole ring, sulfonyl, and halogen groups. Based on the interaction with 
crucial residues in the active site comparable to the selective inhibitor, 
CR2 can be concluded to be an anti-melanoma through the inhibition 
of Braf-kinase. Overall docking studies showed that the van der Waals 
forces were the dominant key players favoring the interactions. Docking 
scores (fitness energy kcal/mol) of ligands with the targets is shown in 
Table 5. The pharmacophore model of CR2 shows seven spatial features: 
Three aromatic, two acceptors, one hydrophobic, and one positive 
group (Fig. 6). It can be noticed that the two aromatic features of CR2 
contribute much to the non-bonded van der Waals interactions, which 
Fig. 3: Docking of CR2 with dihydrofolate reductase of 
Mycobacterium tuberculosis (Green dash lines-hydrogen bonds, 
red arcs-non-bonded van der Waals interaction)
Fig. 4: Docking of CR2 with Gyrase of Staphylococcus showing 
interactions with crucial active site residues
Fig. 5: Docking of CR2 with human Braf kinase showing bonded 
and non-bonded interactions with crucial active site residues
Fig. 6: Pharmacophore model of CR2 (orange-aromatic, green-
acceptor, blue-positive, black-hydrophobic). The distance and 
angle measurements are shown only for the shared features
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were the dominant player of target interactions. The pharmacophoric 
features of all four ligands are tabulated (Table 6).
A pair-wise alignment was done between pharmacophore of CR2 and 
other co-crystal ligands to study the common pharmacophoric features 
shared by them. The score of the pair-wise alignment reflects their 
matched features. This pharmacophore information will guide us in 
designing lead compounds against the particular target. The shared 
pharmacophoric features between CR2 and the co-crystal ligands serve 
as a valid proof for a similar kind of interaction with the target proteins. 
The docking results also show the participation of the acceptor feature 
of CR2 in the hydrogen bond formation and the aromatic features in the 
non-bonded interactions with the active site residues thus validating 
the pharmacophore finding and the docking results. The superposition 
of pharmacophore models of all four ligands was also done to find 
the common features shared by the different structures (Fig. 7). The 
scores indicate that the features required by the co-crystal ligands to 
elicit the necessary biological activity against the specified targets are 
also present in the ligand CR2 thus supporting the docking protocol 
followed. All ligands share two aromatic features and an acceptor 
feature in common (Table 7).
The computational studies revealed that the ligand (CR2) has 
favorable bonded and non-bonded interactions with the crucial active 
site residues as comparable to the co-crystal inhibitors. They have 
similar kind of pharmacophoric features as like the known inhibitors. 
Therefore, this compound will perform the function and the activity of 
the known and the co-crystal inhibitors with which it was compared. 
The various biological capabilities of other indole based compounds 
have been reported recently [19-21]. Hence, this work has extended the 
scope of developing the phenyl sulfonyl indole derivative compound 
as promising antitubercular, antibacterial, and anti-melanoma agents 
targeting the above-mentioned receptors. This compound could further 
be evaluated for these biological activities based on the supporting 
evidence from computational approaches.
CONCLUSIONS
The chemical structure of the synthesized compound was determined 
by single X-ray diffraction studies. The computer based methods are 
routinely and extensively used to reduce cost and time of drug discovery. 
Hence to identify the potential pharmacological role of the ligand CR2, 
the generic algorithm based molecular docking was performed. The 
studies of CR2 into the active site of the potential targets showed more 
favorable interactions. The van der Waals forces play the predominant 
role in the interactions. These facts are supported by the pharmacophore 
information of the compound. The pharmacophore details of the 
compound, CR2 indicate clearly that the pharmacological role is due to 
the spatial arrangement of two aromatic groups and an acceptor in a 
preferred geometry. The oral bioavailability is inversely proportional to 
TPSA. The predicted topological surface area of the compound supports 
the fact that it might have better oral ABS. The compounds with indole 
moiety have already been proved to have many biological roles. The 
interactions of CR2 with the crucial residues of the targets describe the 
potential applications of this compound as a promising antitubercular, 
antibacterial, and anti-melanoma candidate. The new insights of this 
compound as predicted by the computational methods are believed 
to provide a platform for the futuristic pharmacological activities of 
this compound that can be further considered for other experimental 
techniques.
Supplementary information
Supplementary data and figures of the compound are available from the 
IUCr electronic archives (Reference: GK2338).
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